Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease

References

• Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–71.
   PubMed Web of Science ®Google Scholar
• Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Specchia G, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82:269–72.
   PubMed Web of Science ®Google Scholar
• Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis. 2002;13:S1–6.
   PubMedGoogle Scholar
• Badimon L, Vilahur G. Platelets, arterial thrombosis and cerebral ischemia. Cerebrovasc Dis. 2007;24 :S30–9.
   Google Scholar
• Ogren M, Hedblad B, Isacsson SO, Janzon L, Jungquist G, Lindell SE. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet. 1993;342:1138–41.
   PubMedGoogle Scholar
• Davies MG. Critical limb ischemia: epidemiology. Methodist Debakey Cardiovasc J. 2012;8:10–14.
   PubMedGoogle Scholar
• Lambert MA, Belch JJ. Medical management of critical limb ischaemia: where do we stand today? J Intern Med. 2013;274:295–307.
   Google Scholar
• Meru AV, Mittra S, Thyagarajan B, Chugh A. Intermittent claudication: an overview. Atherosclerosis. 2006;187:221–37.
   PubMed Web of Science ®Google Scholar
• Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ. 1996;313:1440–4.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC-II). J Vasc Surg. 2007;45:S5–67.
   PubMed Web of Science ®Google Scholar
• Sanna G, Alesso D, Mediati M, Cimminiello C, Borghi C, Fazzari AL, et al. Prevalence of peripheral arterial disease in subjects with moderate cardiovascular risk: Italian results from the PANDORA study Data from PANDORA (Prevalence of peripheral Arterial disease in subjects with moderate CVD risk, with No overt vascular Diseases nor Diabetes mellitus). BMC Cardiovasc Disord. 2011;11:59.
   PubMed Web of Science ®Google Scholar
• Violi F, Davi G, Hiatt W, Lip GY, Corazza GR, Perticone F, et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol. 2013;62:2255–6.
   Google Scholar
• Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak J, et al.; The Cardiovascular Health Study Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999; 19:538–45.
   PubMed Web of Science ®Google Scholar
• Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109:733–9.
   PubMed Web of Science ®Google Scholar
• Van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004;109:1089–94.
   PubMed Web of Science ®Google Scholar
• Dormandy JA. Natural history of intermittent claudication. Hospital Update. 1991;April:314–18.
   Google Scholar
• Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257–64.
   PubMed Web of Science ®Google Scholar
• Criqui MH. Peripheral arterial disease: epidemiological aspects. Vasc Med. 2001;6:S3–7.
   PubMed Web of Science ®Google Scholar
• McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an indipendent predictor of mortality. Atherosclerosis. 1991;87:119–28.
   PubMed Web of Science ®Google Scholar
• Beckera F, Robert-Ebadia H, Riccob JB, Setaccic C, Cao P, de Donato G, et al. Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011;42:S4–12.
   Google Scholar
• Street TK. What the primary care provider needs to know for limb salvage. Methodist Debakey Cardiovasc J. 2012;8:57–9.
   Google Scholar
• O’Connell JB, Quiñones-Baldrich WJ. Proper evaluation and management of acute embolic versus thrombotic limb ischemia. Semin Vasc Surg. 2009;22:10–16.
   Google Scholar
• Walker TG. Acute limb ischemia. Tech Vasc Interv Radiol. 2009;12: 117–29.
   Google Scholar
• Lawall H, Zemmrich C, Bramlage P, Amann B. Health related quality of life in patients with critical limb ischemia. Vasa. 2012;41:78–88.
   Google Scholar
• Huppert P, Tacke J, Lawall H; Deutschen Gesellschaft für Angiologie/Gefässmedizin. [S3 guidelines for diagnostics and treatment of peripheral arterial occlusive disease]. Radiologe. 2010;50:7–15. [In German]
   Google Scholar
• Edwards JM, Coldwell DM, Goldman ML, Strandness DE Jr. The role of duplex scanning in the selection of patients for transluminal angioplasty. J Vasc Surg. 1991;13:69–74.
   PubMed Web of Science ®Google Scholar
• Van der Heijden FH, Legemate DA, van Leeuwen MS, Mali WP, Eikelboom BC. Value of duplex scanning in the selection of patients for percutaneous transluminal angioplasty. Eur J Vasc Surg. 1993; 7:71–6.
   Google Scholar
• Mattos MA, van Bemmelen PS, Hodgson KJ, Ramsey DE, Barkmeier LD, Sumner DS. Does correction of stenoses identified with color duplex scanning improve infrainguinal graft patency? J Vasc Surg. 1993;17:54–64.
   Google Scholar
• Bandyk DF, Schmitt DD, Seabrook GR, Adams MB, Towne JB. Monitoring functional patency of in situ saphenous vein bypasses: the impact of a surveillance protocol and elective revision. J Vasc Surg. 1989;9:286–96.
   Google Scholar
• Mills JL, Harris EJ, Taylor LM Jr, Beckett WC, Porter JM. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. J Vasc Surg. 1990;12: 379–86.
   Google Scholar
• Laborde AL, Synn AY, Worsey MJ, Bower TR, Hoballah JJ, Sharp WJ, et al. A prospective comparison of ankle/brachial indices and color duplex imaging in surveillance of the in situ saphenous vein bypass. J Cardiovasc Surg. 1992;33:420–5.
   Google Scholar
• Taylor PR, Tyrrell MR, Crofton M, Bassan B, Grigg M, Wolfe JH, et al. Colour flow imaging in the detection of femoro-distal graft and native artery stenosis: improved criteria. Eur J Vasc Surg. 1992;6:232–6.
   Google Scholar
• Golledge J, Beattie DK, Greenhalgh RM, Davies AH. Have the results of infrainguinal bypass improved with the widespread utilisation of postoperative surveillance? Eur J Vasc Endovasc Surg. 1996;11: 388–92.
   Google Scholar
• Gerhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ. Guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vasc Med. 2006;11: 183–200.
   PubMed Web of Science ®Google Scholar
• Bandyk DF, Cato RF, Towne JB. A low flow velocity predicts failure of femoropopliteal and femorotibial bypass grafts. Surgery. 1985;98: 799–809.
   Google Scholar
• Collins R, Burch J, Cranny G, Aguiar-Ibanez R, Craig D, Wright K, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ. 2007;334:1257.
   PubMedGoogle Scholar
• Collins R, Cranny G, Burch J, Aguiar-Ibanez R, Craig D, Wright K, et al. A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease. Health Technol Assess. 2007;11:1–184.
   Web of Science ®Google Scholar
• Visser K, Hunink MG. Peripheral arterial disease: gadolinium enhanced MR angiography versus color-guided duplex US –a meta-analysis. Radiology. 2000;216:67–77.
   PubMed Web of Science ®Google Scholar
• Blum A, Nahir M. Future non-invasive imaging to detect vascular plaque instability and subclinical non-obstructive atherosclerosis. J Geriatr Cardiol. 2013;10:178–85.
   Google Scholar
• Yuan C, Beach KW, Smith LH, Hatsukami TS. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation. 1998;98:2666–71.
   PubMed Web of Science ®Google Scholar
• Zhang S, Hatsukami TS, Polissar NL, Han C, Yuan C. Comparison of vessel wall area measurement differences among three black blood contrast weighting images. Magn Reson Imaging. 2001;19:795–892.
   PubMed Web of Science ®Google Scholar
• Hatsukami TS, Ross R, Polissar NL, Yuan C. Identification of fibrous cap thickness and cap rupture in human atherosclerotic carotid plaque in-vivo with high resolution magnetic resonance imaging. Circulation. 2000;102:959–64.
   PubMed Web of Science ®Google Scholar
• Mitsumori LM, Hatsukami TS, Ferguson MS, Kervin WS, Cai J, Yuan C. In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. J Magn Reson Imaging. 2003;17:410–20.
   PubMed Web of Science ®Google Scholar
• Yuan C, Zhang SX, Polissar NL, Echelard D, Ortiz G, Dawis JW, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent TIA or stroke. Circulation. 2002;105:2051–6.
   Google Scholar
• Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation. 2001; 104:2051–6.
   PubMed Web of Science ®Google Scholar
• Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002;15: 62–7.
   PubMed Web of Science ®Google Scholar
• Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. Radiology. 2002;223:566–73.
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000;102:506–10.
   PubMed Web of Science ®Google Scholar
• Botnar RM, Stuber M, Kim WY, Danias PG, Manning WJ. Magnetic resonance coronary lumen and vessel wall imaging. Rays. 2001;26: 291–303.
   PubMedGoogle Scholar
• Lowery AJ, Hynes N, Manning BJ, Mahendran M, Tawfik S, Sultan S. A prospective feasibility study of duplex ultrasound arterial mapping, digital-subtraction angiography, and magnetic resonance angiography in management of critical lower limb ischemia by endovascular revascularization. Ann Vasc Surg. 2007;21:443–51.
   Google Scholar
• Koelemay MJ, Lijmer JG, Stoker J, Legemate DA, Bossuyt PM. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA. 2001;285:1338–45.
   PubMed Web of Science ®Google Scholar
• Nelemans PJ, Leiner T, de Vet HC, van Engelshoven JM. Peripheral arterial disease: meta-analysis of the diagnostic performance of MR angiography. Radiology. 2000;217:105–14.
   Google Scholar
• Cao P, Ecksteinb HH, De Rangoc P, Setaccid C, Riccoe JB, de Donato G, et al. Chapter II: diagnostic methods. Eur J Vascular Endovasc Surg. 2011;42:S13–32.
   PubMedGoogle Scholar
• Duran C, Bismuth J. Advanced imaging in limb salvage. Methodist Debakey Cardiovasc J. 2012;8:28–32.
   Google Scholar
• Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJW. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and metaanalysis. JAMA. 2009;301:415–24.
   PubMed Web of Science ®Google Scholar
• Hessel SJ, Adams DF, Abrams HL. Complications of angiography. Radiology. 1981;138:273–81.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Guida A, Camera M, Colli S, Minno GD, Tremoli E. Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med. 2011;43:531–44.
   PubMed Web of Science ®Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al.; Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.
   PubMed Web of Science ®Google Scholar
• Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol. 2009;103(suppl):4A–10A.
   Google Scholar
• Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985;75:328–38.
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989; 321:501–7.
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126–32.
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007; 50:1852–6.
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–7.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/ OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556–66.
   PubMed Web of Science ®Google Scholar
• Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6:3–11.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29:2202–11.
   PubMed Web of Science ®Google Scholar
• Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011;(1):CD008076.
   Google Scholar
• Raju NC, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin mortality in primary prevention of cardiovascular disease. Am J Med. 2011;124:621–9.
   PubMed Web of Science ®Google Scholar
• Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevetion of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based clinical practice Guidelines. Chest. 2012;141(2 Suppl):e669S–90S.
   Google Scholar
• Gandhi S, Weinberg I, Margey R, Jaff MR. Comprehensive medical management of peripheral arterial disease. Prog Cardiovasc Dis. 2011;54:2–13.
   Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–e654.
   PubMed Web of Science ®Google Scholar
• Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta- analysis. Arch Intern Med. 1999;159:337–45.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1555–70.
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007; 45:645–54.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107:757–61.
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481–6.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81: 333–5.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA. The non-lipid effects of statins on endothelial function. Trends Cardiovasc Med. 2006;16:156–62.
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28: 1462–536.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–19.
   PubMed Web of Science ®Google Scholar
• Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53.
   PubMedGoogle Scholar
• ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353: 2643–53.
   PubMed Web of Science ®Google Scholar
• Carter RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella MF, Gilbert GE, et al. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial. Diabetes Care. 2007;30:2646–8.
   Google Scholar
• De Rubertis BG, Pierce M, Ryer EJ, Trocciola S, Kent KC, Faries PL. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg. 2008;47:101–8.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care.2010;33:S11–61.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.
   PubMed Web of Science ®Google Scholar
• Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–7.
   PubMed Web of Science ®Google Scholar
• Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ; CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2009;157:369–74.
   PubMed Web of Science ®Google Scholar
• Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009;(4):CD001246.
   Google Scholar
• Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.
   PubMed Web of Science ®Google Scholar
• Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007;(3):CD005158.
   Google Scholar
• Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008;(1):CD003748.
   Google Scholar
• Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R. Cilostazol, naftidrofuryl oxalate, pentoxifylline, and inositol nicotinate for intermittent claudication in people with peripheral arterial disease. London, UK: National Institute for Health and Clinical Excellence; 2011. pp. 1–252.
   Google Scholar
• Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–30.
   PubMed Web of Science ®Google Scholar
• Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001;87:28D–33D.
   Web of Science ®Google Scholar
• Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention. 2009;5:384–93.
   PubMed Web of Science ®Google Scholar
• Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa. 2004;33:137–44.
   PubMed Web of Science ®Google Scholar
• Prostanoids for chronic critical leg ischemia: a randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ann Intern Med. 1999;130:412–21.
   Google Scholar
• Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev. 2010;(1):CD006544.
   Google Scholar
• Berridge DC, Kessel D, Robertson I. Surgery versus thrombolysis for acute limb ischaemia: initial management. Cochrane Database Syst Rev. 2002;(3):CD002784.
   Google Scholar
• Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220:251–66; discussion 266–8.
   Google Scholar
• Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev. 2010;(3):CD001099.
   Google Scholar
• Balzer KM, Weis-Müller BT. Results of open vascular surgical therapy in chronic peripheral arterial disease. Vasa. 2011;40:359–67.
   Google Scholar
• Dattiloa PB, Casserly IP. Critical limb ischemia: endovascular strategies for limb salvage. Prog Cardiovasc Dis. 2011;54:47–60.
   Google Scholar
• Safian RD, Niazi K, Runyon JP, Dulas D, Weinstock B, Ramaiah V, et al. Orbital atherectomy for infrapopliteal disease: device concept and outcome data for the oasis trial. Catheter Cardiovasc Interv. 2009;73: 406–12.
   PubMed Web of Science ®Google Scholar
• Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (basil): multicentre, randomized controlled trial. Lancet. 2005;366:1925–34.
   PubMed Web of Science ®Google Scholar
• Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975–81.
   PubMed Web of Science ®Google Scholar
• De Vries JP, Karimi A, Fioole B, Van Leersum M, Werson DA, Van Den Heuvel DA. First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: update of technique and results. J Cardiovasc Surg. 2013;54:327–32.
   Google Scholar
• Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, et al. Local drug delivery to prevent restenosis. J Vasc Surg. 2013; 57:1403–14.
   PubMed Web of Science ®Google Scholar
• Minar E. Femoral stenting: what do the guidelines tell us. J Cardiovasc Surg. 2013;54:211–15.
   Google Scholar
• Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc Interv. 2006;68:793–8.
   PubMed Web of Science ®Google Scholar
• Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below- the-knee drug-eluting stents: the paradise (preventing amputations using drug eluting stents) trial. J Am Coll Cardiol. 2010;55:1580–9.
   PubMed Web of Science ®Google Scholar
• Martens JM, Knippenberg B, Vos JA, de Vries JP, Hansen BE, van Overhagen H; PADI Trial Group. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Vasc Surg. 2009;50:687–9.
   Google Scholar
• Kasapis C, Henke PK, Chetcuti SJ, Koenig GC, Rectenwald JE, Krishnamurthy VN, et al. Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:44–55.
   Google Scholar
• Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al.; Zilver PTX trial Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–27.
   PubMed Web of Science ®Google Scholar
• Balzer KM, Sandmann W. Das biologische Verhalten von Homograft s zum arteriellen Gefäßersatz. Gefässchirurgie. 2010;15:101–7.
   Google Scholar
• Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: feasibility and durability. J Vasc Surg. 1997;25:255–70.
   PubMedGoogle Scholar
• Chiu KWH, Davies RSM, Nightingale PG, Bradbury AW, Adam DJ. Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg. 2010; 39:460–71.
   Google Scholar
• Kashyap VS, Pavkov ML, Bena JF, Sarac TP, O‘Hara PJ, Lyden SP, et al. The management of severe aortoiliac occlusive disease: endovascular therapy rivals open reconstruction. J Vasc Surg. 2008;48: 1451–7.
   Google Scholar
• Schwarzwälder U, Zeller T. Debulking procedures: potential device specific indications. Tech Vasc Interv Radiol. 2010;13:43–53.
   Google Scholar
• Dörffler-Melly J, Koopman MM, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005;(1):CD002071.
   Google Scholar
• Schweizer J, Müller A, Forkmann L, Hellner G, Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology. 2001;52:659–69.
   Google Scholar
• Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2008;(4):CD000535.
   Google Scholar
• Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52:825–33.
   PubMed Web of Science ®Google Scholar
• Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet. 2000;355:346–51.
   PubMed Web of Science ®Google Scholar
• Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2011;141:e637S–68S.
   Google Scholar
• Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103:841–8.
   PubMed Web of Science ®Google Scholar
• Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr Metab Cardiovasc Dis. 2011;21:542–5.
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
   PubMed Web of Science ®Google Scholar
• Di Minno G, Russolillo A, Gambacorta C, Di Minno A, Prisco D. Improving the use of direct oral anticoagulants in atrial fibrillation. Eur J Intern Med. 2013;24:288–94.
   Google Scholar
• De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012;59:1413–25.
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. New Engl J Med. 2013;368:1272–4.
   PubMed Web of Science ®Google Scholar
• Knowles JW, Assimes TL, Li J, Quertermous T, Cooke JP. Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology. Arterioscler Thromb Vasc Biol. 2007;27:2068–78.
   PubMed Web of Science ®Google Scholar
• Katwal AB, Dokun AO. Peripheral arterial disease in diabetes: is there a role for genetics? Curr Diab Rep. 2011;11:218–25.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Zdoukopoulos N. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: the CUMAGAS-PAD database. Am J Epidemiol. 2009;170:1–11.
   PubMed Web of Science ®Google Scholar
• Leeper NJ, Kullo IJ, Cooke JP. Genetics of peripheral artery disease. Circulation. 2012;125:3220–8.
   PubMed Web of Science ®Google Scholar
• Violi F, Lip GYH, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med. 2012;7:213–18.
   Google Scholar
• Garimella PS, Hart PD, O’Hare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. Am J Kidney Dis. 2012; 60:641–54.
   PubMed Web of Science ®Google Scholar
• O’Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2838–47.
   PubMed Web of Science ®Google Scholar
• Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis. 1996;120:25–35.
   PubMedGoogle Scholar
• Sarnak M, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.
   PubMed Web of Science ®Google Scholar
• Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921–9.
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation.2004;110:738–43.
   Google Scholar
• Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985;33:13–18.
   PubMed Web of Science ®Google Scholar
• Mackaay AJ, Beks PJ, Dur AH, Bischoff M, Scholma J, Heine RJ, et al. The distribution of peripheral vascular disease in a Dutch Caucasian population: comparison of type II diabetic and non-diabetic subjects. Eur J Vasc Endovasc Surg. 1995;9:170–5.
   Google Scholar
• Dosluoglu HH, Lall P, Nader ND, Harris LM, Dryjski ML. Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia. J Vasc Surg. 2010;51:1178–89.
   Google Scholar
• Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433–7.
   PubMed Web of Science ®Google Scholar
• Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care. 1989;12:24–31.
   PubMed Web of Science ®Google Scholar
• Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2006;180:389–97.
   Google Scholar
• Ankle Brachial Index Collaboration; Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
   PubMed Web of Science ®Google Scholar
• Bertelè V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni EG. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc Surg. 1999;18:401–10.
   Google Scholar
• Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 2012;126:491–500.
   Google Scholar
• Davies MG. Critical limb ischemia: cell and molecular therapies for limb salvage. Methodist Debakey Cardiovasc J. 2012;8:20–7.
   Google Scholar
• Rioufol G, Finet G, Ginon I, André-Fouët X, Rossi R, Vialle E, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002; 106:804–8.
   PubMed Web of Science ®Google Scholar